Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2006 Apr;8(4):279-89.
doi: 10.1593/neo.05607.

Aberrant Wnt/beta-catenin signaling in pancreatic adenocarcinoma

Gang Zeng  1 , Matt Germinaro, Amanda Micsenyi, Navjot K Monga, Aaron Bell, Ajit Sood, Vanita Malhotra, Neena Sood, Vandana Midda, Dulabh K Monga, Demetrius M Kokkinakis, Satdarshan P S Monga
Affiliations

Aberrant Wnt/beta-catenin signaling in pancreatic adenocarcinoma

Gang Zeng et al. Neoplasia. 2006 Apr.

Abstract

Wnt/beta-catenin signaling plays an important role in normal development. However, its aberrant activation is associated with several cancers. The aim of this study is to examine the Wnt/beta-catenin pathway in patients with advanced pancreatic adenocarcinoma (n = 31). Paraffin sections from tumors (n = 16) and normal pancreata (n = 3) were used to determine the localization of beta-catenin. An additional 15 frozen tumors, adjacent normal pancreata (n = 5), or normal pancreata (n = 4) were utilized for protein isolation. Tumors were also examined for mutations in exon 3 of the CTNNB1 gene. More than 65% of the tumors showed an increase in total beta-catenin, consistent with its enhanced membranous, cytoplasmic, and nuclear localization, but only two showed mutations in CTNNB1. The majority of the remaining tumors demonstrated concurrent increases in Wnt-1 and frizzled-2 (positive regulators) and a decrease in Ser45/Thr41-phospho-beta-catenin. Electrophoretic mobility shift assay demonstrated beta-catenin-T-cell factor binding in tumors only. Adenomatous polyposis coli and axin, which are both negative regulators, remained unchanged. Unexpectedly, total glycogen synthase kinase-3beta protein was elevated in these tumors. Elevated levels of E-cadherin were also observed, although E-cadherin-beta-catenin association in tumors remained unaffected. Thus, Wnt/beta-catenin activation was observed in 65% of pancreatic adenocarcinomas, independently of beta-catenin gene mutations in most tumors.

PubMed Disclaimer

Figures

Figure 1
Figure 1
β-Catenin undergoes redistribution in the majority of pancreatic adenocarcinomas. (A) A representative section from a normal pancreas, obtained through autopsy, shows predominantly membranous localization in tall columnar acinar cells. Inset: Higher magnification highlights membranous localization (white arrowhead). (B–G) Representative tumors from six patients show aberrant β-catenin localization. Insets: Higher magnification clearly demonstrates increased nuclear (arrow) and cytoplasmic (arrowhead) β-catenin localization in pancreatic adenocarcinoma, while still maintaining membranous localization (white arrowhead). (H) A representative tumor from the minor subset of tumors shows normal membranous localization of β-catenin. Inset: Higher magnification shows membranous localization (white arrowhead) of β-catenin in this tumor.
Figure 2
Figure 2
An approximately five-fold increase in arbitrary immunohistochemical score was observed in pancreatic tumors (n = 16) versus normal pancreata (n = 3), which was statistically significant (P < .05).
Figure 3
Figure 3
Activation of the Wnt/β-catenin pathway in the majority of pancreatic adenocarcinomas. (A) Western blot analysis from four representative tumors that display increased total β-catenin protein compared to their adjacent normal pancreata (upper panel) or independent normal pancreata (lower panel). β-Actin demonstrates comparable loading of proteins. The c-myc protein remains unchanged between tumors and adjacent normal pancreata in the upper panel. (B) A representative Western blot analysis using nuclear lysates from a tumor that displayed increased total levels of β-catenin shows increased nuclear β-catenin as well. EMSA detects the β-catenin-TCF complex (arrow) in tumors and not in adjacent normal pancreas in a representative analysis. (C) Representative Western blot analyses for the status of canonical Wnt pathway in two tumors that display elevated total β-catenin reveal elevated Wnt-1 and frizzled-2 in tumors compared to normal adjacent (left set) or true normal pancreata (right set). No change in axin orAPC was detected; however, an unexpected increase in GSK3β was evident in tumors only. Although Ser33,37/Thr41-phosphorylated β-catenin showed either no change (left set) or an increase in tumor (right set) compared to their respective controls, Ser45/Thr41-phosphorylated β-catenin levels were decreased in tumors, again suggesting the stabilization of β-catenin as a mechanism of its increase and activation. β-Actin blot shows equal protein loading.
Figure 4
Figure 4
Missense point mutations in the β-catenin gene in pancreatic tumors in two patients FT2 (upper panel) and FT14 (lower panel). Sequence analysis shows S33C (A) and S37F (B) mutations.
Figure 5
Figure 5
Continued and increased E-cadherin localization at the membrane in pancreatic tumors. (A) A representative section from normal pancreata shows membranous localization (arrow) of β-catenin with some subcellular stainings. (B and C) Representative analysis from two tumors reveals continued membranous localization (arrow) of E-cadherin with increased intensity and some cytoplasmic staining as well. (D) A representative section from a tumor shows comparable E-cadherin localization or intensity at the membrane (arrow) to the control.
Figure 6
Figure 6
Increased E-cadherin level and its continued interaction with β-catenin is observed in pancreatic adenocarcinoma. (A) Two pairs of tumors and normal pancreata atthe upper left panel show increased levels of total E-cadherin in this representative Western blot analysis. The right pair shows no change. The bottom panels show β-actin as a loading control. (B) A representative coprecipitation study shows continued β-catenin-E-cadherin association (middle panel) in pancreatic adenocarcinomas in most tumors, which was a function of immunoprecipitated β-catenin in lysates (bottom panel). No tyrosine phosphorylation of β-catenin was detectable (top panel).
Figure 7
Figure 7
Summary of changes in the Wnt/β-catenin pathway in pancreatic adenocarcinoma. β-Catenin activation in the form of cytoplasmic stabilization and nuclear translocation occurs secondary to increased Wnt-1 or frizzled-2 proteins or mutations in β-catenin gene (CTNNB1). This is complemented by failure of increases in β-catenin's degradation complex proteins, such as axin and APC. GSK3β increase appears inadequate as reflected by decreased phosphorylation of β-catenin at Ser45 and Thr41. The E-cadherin-β-catenin complex's contribution to cytoplasmic or nuclear β-catenin appears highly unlikely due to continued association and absent tyrosine phosphorylation. A more protective response of this complex to sequester some of the stabilized cytoplasmic β-catenins, especially in nonmetastatic tumors, could be an alternative explanation.
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

See all "Cited by" articles

References

    1. Jemal A, Murray T, Ward E, Samuels A, Tiwari RC, Ghafour A, Feuer EJ, Thurn MJ. Cancer statistics, 2005. CA Cancer J Clin. 2005;55(1):10–30. - PubMed
    1. Beger HG, Rau B, Gansauge F, Poch B, Link KH. Treatment of pancreatic cancer: challenge of the facts. World J Surg. 2003;27(10):1075–1084. - PubMed
    1. de La Coste A, Romagnolo B, Billuart P, Renard CA, Buendia MA, Soubrane O, Fabre M, Chelly J, Beldjord C, Kahn A, et al. Somatic mutations of the beta-catenin gene are frequent in mouse and human hepatocellular carcinomas. Proc Natl Acad Sci USA. 1998;95(15):8847–8851. - PMC - PubMed
    1. Hugh TJ, Dillon SA, O'Dowd G, Getty B, Pignatelli M, Poston GJ, Kinsella AR. Beta-catenin expression in primary and metastatic colorectal carcinoma. Int J Cancer. 1999;82(4):504–511. - PubMed
    1. Jaiswal AS, Kennedy CH, Narayan S. A correlation of APC and c-myc mRNA levels in lung cancer cell lines. Oncol Rep. 1999;6(6):1253–1256. - PubMed

Publication types

LinkOut - more resources

-